These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39050574)

  • 1. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review.
    Elsabah H; Ghasoub R; El Omri H; Benkhadra M; Cherif H; Taha RY
    Front Oncol; 2024; 14():1390747. PubMed ID: 39050574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.
    Vo K; Guan T; Banerjee R; Lo M; Young R; Shah N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1244-1248. PubMed ID: 35084252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
    Ceglédi A; Csukly Z; Fekete M; Kozma A; Szemlaky Z; Andrikovics H; Mikala G
    Pathol Oncol Res; 2023; 29():1611375. PubMed ID: 38025905
    [No Abstract]   [Full Text] [Related]  

  • 5. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
    Kupsh A; Arnall J; Voorhees P
    J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report.
    Yang Y; Fu LJ; Chen CM; Hu MW
    World J Clin Cases; 2021 Feb; 9(5):1175-1183. PubMed ID: 33644182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
    Tang ASO; Ahmad Asnawi AW; Koh AZY; Chong SL; Liew PK; Selvaratnam V; Md Fauzi A; Lau NS; Tan SM
    Am J Case Rep; 2023 Mar; 24():e938868. PubMed ID: 36882990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
    Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
    J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.
    Szita VR; Mikala G; Kozma A; Fábián J; Hardi A; Alizadeh H; Rajnics P; Rejtő L; Szendrei T; Váróczy L; Nagy Z; Illés Á; Vályi-Nagy I; Masszi T; Varga G
    Pathol Oncol Res; 2022; 28():1610276. PubMed ID: 35295611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy.
    Deng J; Lin Y; Zhao D; Tong C; Chang AH; Chen W; Gao W
    Front Oncol; 2022; 12():901266. PubMed ID: 36212423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
    AlZahrani A; Alsuhebany N; Tailor IK; Alrajhi AM
    Hematology; 2024 Dec; 29(1):2296809. PubMed ID: 38149670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation.
    Yang CL; Jiang NG; Zhang L; Shen K; Wu Y
    Ther Adv Hematol; 2021; 12():2040620721989578. PubMed ID: 33796234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Gonsalves WI; Buadi FK; Kumar SK
    Eur J Haematol; 2018 Feb; 100(2):215-217. PubMed ID: 29064593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
    Wang L; Lin N
    Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
    Abu Zaanona MI; Patel P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy].
    Szita VR; Wiedemann Á; Syoreni S; Tóth A; Ruff E; Gaál L; Masszi T; Varga G
    Orv Hetil; 2023 Jun; 164(23):894-899. PubMed ID: 37302128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.